Paizu Use In Pregnancy & Lactation

Pregnancy: There are no or a limited amount of data from the use of piperacillin/tazobactam in pregnant women.
Studies in animals have shown developmental toxicity, but no evidence of teratogenicity, at doses that are maternally toxic (see Pharmacology: Toxicology: Preclinical safety data under Actions). Piperacillin and tazobactam cross the placenta.
Piperacillin/tazobactam should only be used during pregnancy if clearly indicated, i.e. only if the expected benefit outweighs the possible risks to the pregnant woman and foetus.
Breast-feeding: Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied. Women who are breastfeeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.
Fertility: A fertility study in rats showed no effect on fertility and mating after intraperitoneal administration of tazobactam or the combination piperacillin/tazobactam (see Pharmacology: Toxicology: Preclinical safety data under Actions).